These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9157988)

  • 1. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
    Chu XY; Kato Y; Sugiyama Y
    Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
    Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
    Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
    Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
    Sugiyama Y; Kato Y; Chu X
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.
    Chu XY; Kato Y; Sugiyama Y
    Drug Metab Dispos; 1999 Apr; 27(4):440-1. PubMed ID: 10101137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
    Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
    J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR).
    Ishizuka H; Konno K; Naganuma H; Sasahara K; Kawahara Y; Niinuma K; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1304-11. PubMed ID: 9067317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide.
    Niinuma K; Takenaka O; Horie T; Kobayashi K; Kato Y; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Aug; 282(2):866-72. PubMed ID: 9262353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
    Sasabe H; Tsuji A; Sugiyama Y
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1033-9. PubMed ID: 9495864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane.
    Akhteruzzaman S; Kato Y; Hisaka A; Sugiyama Y
    J Pharmacol Exp Ther; 1999 Feb; 288(2):575-81. PubMed ID: 9918561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan.
    Nishino A; Kato Y; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1146-8. PubMed ID: 10997931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.
    Yamazaki M; Akiyama S; Ni'inuma K; Nishigaki R; Sugiyama Y
    Drug Metab Dispos; 1997 Oct; 25(10):1123-9. PubMed ID: 9321514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2.
    Morikawa A; Goto Y; Suzuki H; Hirohashi T; Sugiyama Y
    Pharm Res; 2000 May; 17(5):546-52. PubMed ID: 10888306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats.
    Scott DO; Bindra DS; Sutton SC; Stella VJ
    Drug Metab Dispos; 1994; 22(3):438-42. PubMed ID: 8070321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
    Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.